Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 13/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682822 | 0.88 | PTK2 (0.48) | PTK2MAP4K4ATRMAPK14POLQ | |
| SCHEMBL1682852 | 0.85 | PTK2 (0.60) | PTK2MAP4K4ATR | |
| SCHEMBL1682792 | 0.80 | PTK2 (0.56) | PTK2 | |
| SCHEMBL1682854 | 0.75 | PTK2 (0.65) | PTK2MAP4K4 | |
| SCHEMBL13519120 | 0.74 | PTK2 (0.41) | PTK2ATR | |
| SCHEMBL1682860 | 0.71 | PTK2 (0.57) | PTK2MAP4K4 | |
| SCHEMBL1682828 | 0.70 | PTK2 (0.68) | PTK2 | |
| SCHEMBL1682856 | 0.69 | PTK2 (0.63) | PTK2 | |
| SCHEMBL15730263 | 0.68 | MAPK14 (0.56) | MAPK14KDRPOLQ | |
| SCHEMBL18136768 | 0.68 | SMYD3 (0.49) | MAP4K4ATRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586580-B2 | 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-01 | — | — | US | disclosed |
| EP-2491043-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KIST Korea Institute of Science and Technology (KR) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049332-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049332-A2 | 2,7-SUBSTITUTED THIENO[3,2-D]PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277424-A1 | 2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK2, TK1, DTYMK | PTK2 292/4885MAP4K4 72/4885ATR 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.